Optimal timing of vitamin k antagonist resumption after upper gastrointestinal bleeding a risk modelling analysis

Thrombosis and Haemostasis

Volumn 117, Issue 3, 2017, Pages 491-499

  Majeed, Ammar ^a,b,c   Wallvik, Niklas ^d   Eriksson, Joakim ^d   Höijer, Jonas ^b   Bottai, Matteo ^b   Holmström, Margareta ^a   Schulman, Sam ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c The Alfred Health ^*  (Australia)

^d UMEÅ UNIVERSITY   (Sweden)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Gastrointestinal bleeding; Mortality; Stroke; Thromboembolism; Warfarin

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; MORTALITY; PRIORITY JOURNAL; THROMBOEMBOLISM; UPPER GASTROINTESTINAL BLEEDING; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; KAPLAN MEIER METHOD; MULTICENTER STUDY; ONTARIO; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME FACTOR; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CLINICAL DECISION-MAKING; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; ONTARIO; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; THROMBOEMBOLISM; TIME FACTORS; VITAMIN K;

EID: 85014222847     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-07-0498     Document Type: Article

References (17)

1. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
2. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of lifethreatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Internal Med 1996; 156: 1197-1201.
3. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113: 662-668.
4. Witt D, Delate T, Garcia D, et al. Risk of thromboembolism, recurrent haemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Internal Med 2012; 172: 1484-1491.
5. Johnsen SP, Sørensen HT, Mellemkjoer L, et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001; 86: 563-568.
6. Salem DN, O’Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidellines (8th Edition). Chest 133: 593S-629S.
7. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
8. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidellines (8th Edition). Chest 2008; 133: 454S-545S.
9. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
10. Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost 2015; 114: 819-825.
11. Staerk L, Lip G, Olesen J, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. Br Med J 2015; 351: h5876.
12. Sengupta N, Feuerstein JD, Patwardhan VR, et al. The risks of thromboembolism vs recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 2015; 110: 328-335.
13. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 2001; 323: 1218-1222.
14. MacLean S, Mulla S, Akl E, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidellines. Chest 2012; 141: e1S-23S.
15. Hearnshaw SA, Logan RF, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335.
16. Loperfido S, Fabris L, Maifreni L, et al. Comparison of upper gastrointestinal bleeding in UK and in Treviso area (Italy): similarities and differences. Gut 2012; 61: 1641-1642.
17. Van Walraven C, Hart R, Singer D, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc 2002; 288: 2441-2448.